A peptide from the first fibronectin domain of NCAM acts as an inverse agonist and stimulates FGF receptor activation, neurite outgrowth and survival.
Neural cell adhesion molecule (NCAM) contributes to axon growth and guidance during development and learning and memory in adulthood. Although the Ig domains mediate homophilic binding, outgrowth activity localizes to two membrane proximal fibronectin-like domains. The first of these contains a site identified as a potential FGF receptor (FGFR) activation motif (FRM) important for NCAM stimulation of neurite outgrowth, but its activity has hitherto remained hypothetical. Here, we have tested the effects of a domain-specific antibody and peptides corresponding to the FRM in cellular assays in vitro. The first fibronectin domain antibody inhibited NCAM-stimulated outgrowth, indicating the importance of the domain for NCAM function. Monomeric FRM peptide behaved as an inverse agonist; low concentrations specifically inhibited neurite outgrowth stimulated by NCAM and cellular responses to FGF2, while saturating concentrations stimulated FGFR-dependent neurite outgrowth equivalent to NCAM itself. Dendrimeric FRM peptide was 125-fold more active and stimulated FGFR activation, FGFR-dependent and FGF-mimetic neurite outgrowth and cell survival (but not proliferation). We conclude that the FRM peptide contains NCAM-mimetic bioactivity accounted for by stimulation of FGF signalling pathways at the level of or upstream from FGF receptors, and discuss the possibility that FRM comprises part of an FGFR activation site on NCAM.
Anderson
Alexandra A
AA
Division of Cell and Molecular Biology, Faculty of Life Sciences, Imperial College London, London, UK.
Kendal
Claire E
CE
Garcia-Maya
Mitla
M
Kenny
Anna V
AV
Morris-Triggs
Samantha A
SA
Wu
Teresa
T
Reynolds
Richard
R
Hohenester
Erhard
E
Saffell
Jane L
JL
D016475:3T3 Cells; D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D000963:Antimetabolites / Q000494:pharmacology; D001711:Biotransformation / Q000187:drug effects; D001973:Bromodeoxyuridine / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003500:Cyclization; D005353:Fibronectins / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D008958:Models, Molecular; D019006:Neural Cell Adhesion Molecules / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D016501:Neurites / Q000187:drug effects / Q000502:physiology*; D009836:Oligodendroglia / Q000187:drug effects; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology*; D011487:Protein Conformation; D051381:Rats; D017468:Receptors, Fibroblast Growth Factor / Q000819:agonists*
D019138:Antibodies, Blocking; D000963:Antimetabolites; D005353:Fibronectins; D019006:Neural Cell Adhesion Molecules; D010446:Peptide Fragments; D017468:Receptors, Fibroblast Growth Factor; D001973:Bromodeoxyuridine